Biomedical Engineering Reference
In-Depth Information
46. Soucie JM, Nuss R, Evatt B, et al. (2000) Mortality among
males with hemophilia relationship with source of medical
care: the hemophilia surveillance system project investiga-
tors. Blood, 96(2), 437-442.
47. Bj
€
orkman S, Berntorp E. (2001) Pharmacokinetics of coagu-
lation factors: clinical relevance for patients with haemo-
philia. Clin. Pharmacokinet. 40, 815-832.
48. B j
61. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV,
Lu Q, et al. (2010) Prolonged activity of factor IX as a
monomeric Fc fusion protein. Blood 115, 2057-2064.
62. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy
KP, Timony GA, et al. (1996) Recombinant human factor IX:
replacement therapy, prophylaxis, and pharmacokinetics in
canine hemophilia B. Blood 88, 2603-2610.
63. McCarthy K, Stewart P, Sigman J, Read M, Keith JCJr,
Brinkhous KM, et al. (2002) Pharmacokinetics of recombi-
nant factor IX after intravenous and subcutaneous adminis-
tration in dogs and cynomolgus monkeys. Thromb. Haemost.
87, 824-830.
64. Shapiro AD, Ragni M, Valentino L, et al. (2010) Safety and
prolonged biological activity following a single administra-
tion of a recombinant molecular fusion of native human
coagulation factor IX and the Fc region of immunoglobulin
G (IgG) (rFIXFc) to subjects with hemophilia B. Haemo-
philia 16(Suppl. 4), 30.
65. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC,
Powell JS, et al. (2012) Recombinant factor IX-Fc fusion protein
(rFIXFc) demonstrates safety and prolonged activity in a Phase
1/2a study in hemophilia B patients. Blood 119(3), 666-672.
66. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy
KL. (2001) Human recombinant factor IX: safety and efficacy
studies in hemophilia B patients previously treated with
plasma-derived factor IX concentrates. Blood 98, 3600-3606.
67. BeneFIX
1
(coagulation factor IX Recombinant) Summary of
ProductCharacteristics forBeneFIX, ElectronicMedicinesCom-
pendium 20 10, http://www.medicines.org.uk/emc/medicine/
20 37 6/ SP C /B e ne FIX /# PH AR MACO DY NA MI C _P RO PS .
accessed November 6, 2011.
68. Schaison G, Young J, Pholsena M, Nahoul K, Couzinet B.
(1993) Failure of combined follicle-stimulating hormone-
testosterone administration to initiate and/or maintain sper-
matogenesis in men with hypogonadotropic hypogonadism.
J. Clin. Endocrinol. Metab. 77, 1545-1549.
69. Schoot DC, Harlin J, Shoham Z, Mannaerts BMJL, Lahlou N,
Bouchard P, et al. (1994) Endocrinology: recombinant human
follicle-stimulating hormone and ovarian response in gonad-
otrophin-deficient women. Hum. Reprod. 9, 1237-1242.
70. Steelman SL, Pohley FM. (1953) Assay of the follicle
stimulating hormone based on the augmentation with human
chorionic gonadotropin. Endocrinology 53, 604-616.
71. Pierce JG, Parsons TF. (1981) Glycoprotein hormones: struc-
ture and function. Annu. Rev. Biochem. 50, 465-495.
72. Jia X-C, Hsueh AJW. (1986) Granulosa cell aromatase bio-
assay for follicle-stimulating hormone: validation and appli-
cation of the method. Endocrinology 119, 1570-1577.
73. Keene JL, Matzuk MM, Otani T, Fauser BC, Galway AB,
Hsueh AJ, et al. (1989) Expression of biologically active
human follitropin in Chinese hamster ovary cells. J. Biol.
Chem. 264, 4769-4775.
74. de Leeuw R, Mulders J, Voortman G, Rombout F, Damm J,
Kloosterboer L. (1996) Recombinat hormones: structure-
function relationship of recombinant follicle stimulating
hormone (Puregon
1
). Mol. Hum. Reprod. 2, 361-369.
€
onsson S. (2009) Pharmaco-
ki ne tics a nd dos e requirements of f actor VIII ove r the age
rang e 3- 74 ye a rs: a popul ation analysis ba sed on 50 patients
w i t h l o ng - t e r m p r o ph y l a c t i c t r e a t m e nt f o r h a e m o p h i l i a A .
Eu r . J . C l i n . P h ar m a c ol . June 26, 2009. [Epub ahead
of p r i nt ] .
49. Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L,
Oswaldsson U, et al. (2001) Structural and functional char-
acteristics of the B-domain-deleted recombinant factor VIII
protein, r-VIII SQ. Thromb. Haemost. 85, 93-100.
50. Toole J, Pittman D, Orr E. (1986) A large region (
¼
95 kDa) of
human factor VIII is dispensable for in vitro procoagulant
activity. Proc. Natl. Acad. Sci. USA 83, 5939-5942.
51. Graham JB, Buckwalter JA, Hartley LJ, Brinkhous KM.
(1949) Canine hemophilia; observations on the course, the
clotting anomaly, and the effect of blood transfusions. J. Exp.
Med. 90, 97-111.
52. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC,
et al. (2002) The Chapel Hill hemophilia A dog colony
exhibits a
€
or k m a n S , Fo l ke s s o n A , J
factor VIII gene
inversion. PNAS USA 99,
12991-12996.
53. Dumont J, Liu T, Low S, Zhang X, Kamphaus GD, Sakorafas
P, Fraley C, Drager D, Reidy T, McCue J, Franck HWG,
Merricks EP, Nichols TC, Ashworth T, Franck H, Merricks
EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H. (2012)
Prolonged activity of a recombinant factor VIII-Fc fusion
protein in hemophilia A mice and dogs. Blood, 119(13),
3024-3030.
54. Powell J, Josephson NC, Quon, et al. (2011) Pharmaco-
kinetics and safety of recombinant factor VIII Fc fusion
protein (rFVIIIFc) in a Phase 1/2a trial in previously treated
patients (PTPs) with severe hemophilia A. J. Thromb. Hae-
most. (s2), O-TU-073, 283.
55. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E,
et al. (2012) Safety and prolonged activity of recombinant
factor VIII Fc fusion protein in hemophilia A patients. Blood,
119(13), 3031-3037.
56. Bolton-Maggs PHB, Pasi KJ. (2003) Haemophilias A and B.
Lancet 361, 1801-1809.
57. Green P, Naylor J, Giannelli F. (1995) The hemophilias. Adv.
Genet. 32, 99-139.
58. Limentani SA, Roth DA, Furie BC, Furie B. (1993) Recom-
binant blood clotting proteins for hemophilia therapy. Semin.
Thromb. Hemost. 19, 62-72.
59. Giangrande P. (2005) Haemophilia B: christmas disease.
Expert Opin. Pharmacother. 6, 1517-1524.
60. Lin H-F, Maeda N, Smithies O, Straight DL, Stafford DW.
(1997) A coagulation factor IX-deficient mouse model for
human hemophilia B. Blood 90, 3962-3966.
Search WWH ::
Custom Search